Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Sarcoma, Kaposi 1Respiratory Distress Syndrome 1Pneumonia 1Multi-centric Castleman's Disease 1Hematologic Neoplasms 1Glioblastoma 1Castleman Disease 1Astrocytoma 1Acquired Immunodeficiency Syndrome 1

Interventions

Zidovudine 12Doxorubicin 11Vincristine 9Bleomycin 8Interferon alpha-2 6Methotrexate 5Leucovorin 5Dexamethasone 5Cyclophosphamide 5sargramostim 4Filgrastim 4Cytarabine 4Etoposide 3pomalidomide 2interferon alfa-n1 2Thalidomide 2Rituximab 2Isotretinoin 2Interleukin-2 2Didanosine 2Allopurinol 2tocilizumab 1plerixafor 1liposomal doxorubicin 1interferon gamma-1b 1abemaciclib 1Zalcitabine 1Vinblastine 1Valganciclovir 1Tumor Necrosis Factor-alpha 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Acquired Immunodeficiency Syndrome × tocilizumab × Clear all
NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡